DJIA 17,113.54 61.81 0.36%
NASDAQ 4,456.02 31.31 0.71%
S&P 500 1,983.53 9.90 0.50%
market minute promo

ACTAVIS (NYSE: ACT)

216.37 0.24 (0.11%)

REAL-TIME: Last trade at

Extended Hours: $219.93 $3.56 (1.65%)
Quote as of (NYSE)



company name or ticker

Recent Quotes

ACT $216.37 0.11%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $217.08
Previous Close $216.13
Daily Range $215.97 - $218.47
52-Week Range $124.45 - $230.77
Market Cap $37.7B
P/E Ratio -54.99
Dividend (Yield) $0.00 (0.0%)
Volume 1,479,963
Average Daily Volume 2,321,210
Current FY EPS $13.65

Sector

Healthcare

Industry

Drugs

ACTAVIS (ACT) Description

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products. Website: http://www.actavis.com/

News & Commentary

Is This Drug Maker’s Stock Too Cheap to Ignore?

Teva Pharmaceutical shares have under performed its sector over the past year. Though the company faces a number of issues, most of the bad news may already be priced into the stock. Given the drug maker also appears to have some intriguing opportunities for future growth, are Teva shares too cheap to ignore?

Medicines360 And Actavis Announce FDA Acceptance For Filing Of NDA For Levosertâ„¢ IUD

Synergy Pharmaceuticals Progresses with Mid-Stage Candidate - Analyst Blog

Interesting ACT Put And Call Options For December 20th

3 Health Care Stocks Dragging The Sector Down

Mylan (MYL) Joins the Tax-Inversion Wave - Analyst Blog

Actavis Looks To Keep Up Momentum In Spite Of Yellen's Report

Mylan to Buy Abbott Generic Drug Unit - Analyst Blog

Will Earnings Season Provide The Next Catalyst For Stocks?

3 Stocks Underperforming Today In The Drugs Industry

Synergy Pharmaceuticals' Plecanatide to Move into Phase III - Analyst Blog

See More ACT News...

ACT's Top Competitors

ACT $216.37 (0.11%)
Current stock: ACT
JNJ $102.47 (1.18%)
Current stock: JNJ
NVS $89.26 (0.76%)
Current stock: NVS
RHHBY $36.83 (0.30%)
Current stock: RHHBY